Allos Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the U.S. FDA granted orphan drug designation to the Company's novel antifolate, pralatrexate, for the treatment of patients with diffuse large B-cell lymphoma.
The details can be read here.
No comments:
Post a Comment